by Raynovich Rod | Dec 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Santa Claus Making Fast Tracks Nasdaq is up 1% as of midday trading and life science stocks are strong across the board. The IBB is up 2.29%, XBI up 1.8 %.The holiday spirit pervades. Movers among the Rayno Life Science focus stocks are the usual suspects plus many...
by Raynovich Rod | Dec 16, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
But A Lot of Green Today in Diagnostics and Tools The NASDAQ (4030)and the S&P (1787) are up about 0.7% but biotech stocks are lagging with the IBB ($216) up only 0.33%. Momentum in biopharmaceutical stocks has been easing since a late November move around the...
by Raynovich Rod | Dec 12, 2013 | Biopharmaceuticals
Biotech Bull Market Takes A Breather When the biotech bull market began in Q2 2009 it was value driven because of low technology values and Price/Sales for the widely covered stocks. Product sales were about to explode for many companies and in 2012 the sector took...
by Raynovich Rod | Dec 9, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Weak Tape Today 12/10–Gilead (GILD) Down 4.4% on 15.5M Shares IBB ($218.81) down 1.33% on good volume. GILD fall could be reaction to Abbvie (ABBV $53.55) up 4.5% on Phase 3 Hepatitis C data. Virologic response of ABT-450r is 96% in Genotype 1 patients. Other...
by Raynovich Rod | Dec 4, 2013 | Biopharmaceuticals
Life Science Stocks At Ease After 5% Gain in November Stocks Come Back In Late Day Trading 12/4 After 3 down days with the S&P, biotechnology stocks are holding near sector highs with the IBB at $221. Other widely traded ETFS (PBE,XBI) have also held near their...
by Raynovich Rod | Nov 29, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotechnology Stocks Hits New Highs After A Choppy 60 Days Biotechnology stocks eked out small gains today taking the liquid $4.4B market cap ETF (IBB) to new highs at $225 up 5.58% for the week and 5.94% for the month of November.The $1B market cap ETF (XBI $130.49)...
by Raynovich Rod | Nov 25, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Up until recently the Fidelity Select Biotechnology Fund (FBIOX) has outperformed all ETFs but now the IBB and PBE are leaders over the last 3 months. There have been two recent mini-corrections but over the past two weeks the IBB has soared up almost 15% for the past...
by Raynovich Rod | Nov 22, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Large Cap Biotechs Rocketing Up:BIIB, GILD Despite a flattish Dow and S&P, many life science stocks are surging ahead. There are many movers in the Rayno Biopharmaceutical Portfolio : Biogen Idec BIIB $277) up 10%, Gilead (GILD $74.40) up 3.88% and Regeneron (REGN...
by Raynovich Rod | Nov 19, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Bull Market Intact But Momentum Stocks Taking Hits Most of you know the game. Buy stocks with headline news, new business models, increasing RSI and charts that scream momentum. Examples proliferate: Aegerion (AEGR), Celldex (CLDX), Netflix (NFLX), Tesla (TSLA), 3D...
by Raynovich Rod | Nov 15, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Vertex (VRTX $67) Contrarian Trade Working Vertex is one of the worse performing large cap biotechs over 6 mos. is getting boosted on a $152M royalty deal. “Risk-On “Mode in Biotech Stocks Biotech stocks continue to find buyers with the IBB ($211.70)...
